This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bisphosphonates

Authoring team

Bisphosphonates are stable analogues of pyrophosphate which bind to, and stabilise, bone by inhibiting osteoclastic activity. Bisphosphonates may also directly stimulate formation of bone by osteoblasts (1).

The main indications for bisphosphonates are:

  • Paget's disease of bone
  • hypercalcaemia of malignancy
  • osteoporosis

Bisphosphonates are poorly absorbed after oral ingestion. Further impairment to absorption is caused by food, drinks and drugs containing magnesium, calcium, iron or aluminium salts.

A proportion of bisphosphonate that are absorbed is taken up by, and incorporated into, bone while the remaining fraction is excreted unchanged by the kidneys. Bisphosphonates that have been taken up and incorporated into the skeleton are then only released when the bone is resorbed during turnover.

The oral bisphosphonate medicines prescribed in the UK are:

  • alendronate
  • sodium clodronate
  • disodium etidronate
  • ibandronate
  • risedronate sodium
  • disodium tiludronate

The intravenous/injected bisphosphonates prescribed in the UK are:

  • sodium clodronate
  • ibandronate
  • disodium pamidronate
  • zoledronic acid (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.